Early detection of recurrence and progress using serum steroid profiling by LC–MS/MS in patients with adrenocortical carcinoma
Please always quote using this URN: urn:nbn:de:bvb:20-opus-355839
- Serum liquid chromatography–tandem mass spectrometry (LC–MS/MS) steroid profiling is used for the diagnosis of adrenocortical carcinoma (ACC). Guidelines recommend endocrine work-up in addition to radiological imaging for follow-up in ACC, but data on this topic are scarce. Patients were included in this retrospective study if pre-therapeutic hormone values, regular tumour evaluation by imaging, steroid measurements by LC–MS/MS, and details on therapies were available. The utility of steroid profiles in detecting recurrence or diseaseSerum liquid chromatography–tandem mass spectrometry (LC–MS/MS) steroid profiling is used for the diagnosis of adrenocortical carcinoma (ACC). Guidelines recommend endocrine work-up in addition to radiological imaging for follow-up in ACC, but data on this topic are scarce. Patients were included in this retrospective study if pre-therapeutic hormone values, regular tumour evaluation by imaging, steroid measurements by LC–MS/MS, and details on therapies were available. The utility of steroid profiles in detecting recurrence or disease progression was assessed, whereby “endocrine progress” was defined by an elevation of at least 3 of 13 analysed hormones. Cohort A included 47 patients after R0 resection, of whom 15 experienced recurrence and 32 did not. In cohort B, 52 patients with advanced disease (including 7 patients of cohort A with recurrence) could be evaluated on 74 visits when progressive disease was documented. In 20 of 89 cases with documented disease progression, “endocrine progress” was detectable prior to radiological progress. In these cases, recurrence/progression was detected at a median of 32 days earlier by steroid measurement than by imaging, with 11-deoxycortisol and testosterone being the most sensitive markers. Notably, these patients had significantly larger tumour burden. In conclusion, steroid profiling by LC–MS/MS is of value in detecting recurrent/progressive disease in ACC.…
| Author: | Otilia Kimpel, Barbara AltieriORCiD, Ulrich Dischinger, Carmina Teresa Fuss, Max Kurlbaum, Martin FassnachtORCiD |
|---|---|
| URN: | urn:nbn:de:bvb:20-opus-355839 |
| Document Type: | Journal article |
| Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik I |
| Medizinische Fakultät / Comprehensive Cancer Center Mainfranken | |
| Language: | English |
| Parent Title (English): | Metabolites |
| ISSN: | 2218-1989 |
| Year of Completion: | 2023 |
| Volume: | 14 |
| Issue: | 1 |
| Article Number: | 20 |
| Source: | Metabolites (2024) 14:1, 20. https://doi.org/10.3390/metabo14010020 |
| DOI: | https://doi.org/10.3390/metabo14010020 |
| Sonstige beteiligte Institutionen: | Zentraleinheit Klinische Massenspektrometrie |
| Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
| Tag: | adrenal cancer; follow-up; liquid chromatography–tandem mass spectrometry (LC–MS/MS); steroid measurement |
| Release Date: | 2024/06/10 |
| Date of first Publication: | 2023/12/28 |
| Licence (German): |  CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |